To date, four therapies (i.e., alpelisib, everolimus, inavolisib, and capivasertib), each targeting a single node of the PAM pathway, have been approved when given in combination with ET for the treatment of patients with HR+, HER2− breast cancer whose disease progressed on or after ET in the advanced setting. This evidence concerns the gene ERBB2 and breast carcinoma.